WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 401070

CAS#: 897383-62-9 (free base)

Description: Allitinib, also known as AST1306 and ALS 1306, is a potent, selective, irreversible ErbB2 and EGFR inhibitor. AST-1306 inhibits the enzymatic activities of wild-type epidermal growth factor receptor (EGFR) and ErbB2 as well as EGFR resistant mutant in both cell-free and cell-based systems. AST1306 was found to function as an irreversible inhibitor, most likely through covalent interaction with Cys797 and Cys805 in the catalytic domains of EGFR and ErbB2, respectively. In vivo, AST1306 potently suppressed tumor growth in ErbB2-overexpressing adenocarcinoma xenograft and FVB-2/N(neu) transgenic breast cancer mouse models, but weakly inhibited the growth of EGFR-overexpressing tumor xenografts.

Price and Availability




Allitinib (AST1306) is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 401070
Name: Allitinib
CAS#: 897383-62-9 (free base)
Chemical Formula: C24H18ClFN4O2
Exact Mass: 448.11023
Molecular Weight: 448.87672
Elemental Analysis: C, 64.22; H, 4.04; Cl, 7.90; F, 4.23; N, 12.48; O, 7.13

Related CAS #: 897383-62-9 (free base)   1050500-29-2 (tosylate)    

Synonym: AST1306; AST-1306; AST 1306; ALS1306; ALS-1306; ALS1306; AST 6; AST-6; AST6. Allitinib

IUPAC/Chemical Name: N-[4-[[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]amino]quinazolin-6-yl]acrylamide


InChi Code: InChI=1S/C24H18ClFN4O2/c1-2-23(31)29-17-6-8-21-19(11-17)24(28-14-27-21)30-18-7-9-22(20(25)12-18)32-13-15-4-3-5-16(26)10-15/h2-12,14H,1,13H2,(H,29,31)(H,27,28,30)


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>5 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information



1: Zhang H, Wang YJ, Zhang YK, Wang DS, Kathawala RJ, Patel A, Talele TT, Chen
ZS, Fu LW. AST1306, a potent EGFR inhibitor, antagonizes ATP-binding cassette
subfamily G member 2-mediated multidrug resistance. Cancer Lett. 2014 Aug
1;350(1-2):61-8. doi: 10.1016/j.canlet.2014.04.008. Epub 2014 Apr 18. PubMed
PMID: 24747122.

2: Zhang J, Cao J, Li J, Zhang Y, Chen Z, Peng W, Sun S, Zhao N, Wang J, Zhong D,
Zhang X, Zhang J. A phase I study of AST1306, a novel irreversible EGFR and HER2
kinase inhibitor, in patients with advanced solid tumors. J Hematol Oncol. 2014
Mar 11;7:22. doi: 10.1186/1756-8722-7-22. PubMed PMID: 24612546; PubMed Central
PMCID: PMC4007625.

3: Lin L, Xie C, Gao Z, Chen X, Zhong D. Metabolism and pharmacokinetics of
allitinib in cancer patients: the roles of cytochrome P450s and epoxide hydrolase
in its biotransformation. Drug Metab Dispos. 2014 May;42(5):872-84. doi:
10.1124/dmd.113.056341. Epub 2014 Mar 5. PubMed PMID: 24598282.

4: Lin L, Gao Z, Chen X, Zhong D. Development and validation of a sensitive
LC-MS/MS assay for the simultaneous quantification of allitinib and its two
metabolites in human plasma. J Pharm Biomed Anal. 2013 Dec;86:49-55. doi:
10.1016/j.jpba.2013.07.003. Epub 2013 Jul 19. PubMed PMID: 23973791.

5: Xie H, Lin L, Tong L, Jiang Y, Zheng M, Chen Z, Jiang X, Zhang X, Ren X, Qu W,
Yang Y, Wan H, Chen Y, Zuo J, Jiang H, Geng M, Ding J. AST1306, a novel
irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits
antitumor activity both in vitro and in vivo. PLoS One. 2011;6(7):e21487. doi:
10.1371/journal.pone.0021487. Epub 2011 Jul 18. PubMed PMID: 21789172; PubMed
Central PMCID: PMC3138742.